In The News

WOODBURY, NY, April 11, 2024 – The Lustgarten Foundation, in collaboration with the American Association for Cancer Research (AACR), has announced the 2024 recipients of the Lustgarten-AACR Career Development Awards […]

LUSTGARTEN FUNDED RESEARCH: An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk […]

LUSTGARTEN FUNDED RESEARCH: A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig […]

LUSTGARTEN FUNDED RESEARCH: Researchers at the University of Toronto’s Donnelly Centre for Cellular and Biomolecular Research have found two enzymes that work against the chemotherapy drug gemcitabine, preventing it from effectively treating […]

On Tuesday, March 12, 2024,  we celebrated International Women’s Day at the prestigious Salk Institute for Biological Studies for “The Power of Persistence: Women Transforming Cancer Research & Care.” This […]

With thanks and appreciation to our contributing partner, Let’s Win Pancreatic Cancer. The U.S. Food and Drug Administration has approved irinotecan liposome (ONIVYDE) in combination with oxaliplatin, fluorouracil, and leucovorin, […]

According to a Lustgarten-funded study from Dana-Farber Cancer Institute WOODBURY, NY, January 31, 2024 — Last week, the Journal of the American Medical Association published results from a Lustgarten-funded study […]

Elliot K. Fishman, MD, Professorship in Radiology, Professor of Radiology and Radiological Science at Johns Hopkins Medicine In this interview, he discusses how he uses artificial intelligence in his study […]